News
2020-08-17
CPI partners with Perceptive Engineering and FUJIFILM Diosynth Biotechnologies to improve efficiencies in biologics manufacture
CPI has announced a partnership with Perceptive Engineering and FUJIFILM Diosynth Biotechnologies. The companies will develop a data-driven solution to improve efficiencies during downstream biologics processing, reducing the cost of manufacturing life-saving therapies.
Read more2020-07-23
NOVAVAX AND FUJIFILM DIOSYNTH BIOTECHNOLOGIES INITIATE LARGE SCALE MANUFACTURING OF COVID-19 VACCINE CANDIDATE
Novavax, Inc. and FUJIFILM Diosynth Biotechnologies announced today an agreement to manufacture bulk drug substance for Novavax’ COVID-19 vaccine candidate.
Read more2020-06-17
Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology
Read more2020-06-08
Greffex Inc. Signs Manufacturing Contract with FUJIFILM Diosynth Biotechnologies to Produce Vaccines
Read more2020-06-04
“READY TO SAVE THE WORLD” WITH MASS VACCINE MANUFACTURING
On the show, Chancellor Sharp interviewed Dr. Gerry Farrell, chief operating officer of FUJIFILM Diosynth Biotechnologies, Texas, based in College Station
Read more2020-06-01
Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800
Read more2020-05-07
Developing a Biomanufacturing Platform to Fill a Need
As a contract development and manufacturing organization (CDMO), FUJIFILM Diosynth Biotechnologies’ scientists and engineers need to offer flexible solutions to changing customer requirements.
Read more2020-04-09
Fujifilm announces the start of a phase II clinical trial of its influenza antiviral drug “Avigan® Tablet” for COVID-19 patients in the U.S.
FUJIFILM Corporation announces the initiation of a U.S. phase II clinical trial to evaluate the safety and efficacy of its influenza antiviral drug “Avigan® Tablet” for patients with COVID-19, a respiratory infection caused by the novel SARS-CoV-2 coronavirus.
Read more2018-07-18
A Discussion with Dr. Thomas Page, VP Engineering and Asset Development at Fujifilm Diosynth Biotechnologies
Read more2015-08-25